Visual Universitätsmedizin Mainz

Muhammad Ashfaq Khan

He earned his PhD degree (magna cum laude) in 2018 at Institute of Translational Immunology (TIM) supervised by Prof. Dr. Dr. Detlef Schuppan and has continued his postdoctoral training at TIM. He received his degree of “Master of Science in Biotechnology” in 2012 from Pakistan. He served as a Research Associate at the Department of Pharmacy, COMSATS University, Pakistan. His was awarded academic merit scholarships for pursuing master’s degree in Pakistan as well as in USA.


His research interests include studies on the immunological aspects of novel nutritional factors on chronic liver disease in experimental mouse models of liver diseases involving the postulated paradigm of “gut-liver axis” that transmit inflammatory signals to the liver from the gut as outlined below.

 In addition, he also focuses on novel therapeutic approaches of high translational relevance in experimental mouse models of primary liver cancer that could exhibit sustainable clinical response in patients.
Dr. Khan showcased his research activities on various well reputed scientific platforms such as American Association for the study of liver (AASLD) and The European Association for the Study of the Liver (EASL). He is also a member of the EASL and AASLD communities.  Moreover, he has been awarded several abstracts awards.


 Published Articles

1.  Schuppan D, Ashfaq-Khan M, AiTing Yang, Kim YO. Liver Fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biology, 2018; 68-69: 435-451
(IF: 7.5)
2. Zevallos VF, Raker V, Tenzer S, Calvente C, Ashfaq-Khan M, Rüssel N, Pickert G, Schild H, Steinbrink K, Schuppan D.  Nutritional Wheat Amylase/trypsin Inhibitors Promote intestinal inflammation by myeloid cell activation. Gastroenterology, 2016; 152(5):1100-1113 (IF: 20.7)
3. Schuppan D, Pickert G, Ashfaq-Khan M, Zevallos V. Non-Celiac wheat sensitivity: Differential diagnosis, triggers and implications. Best Practice & Research Clinical Gastroenterology 2015; 29(1):469-476 (IF: 3.7)
4. Akhtar T, Ashfaq-Khan M, Jones PG, Hameed S. A facile one pot synthesis of 2-arylamino-5-aryloxylalkyl-1,3,4-oxadiazoles and their urease inhibition studies. Chemical Biology and Drug Design; 2014; 84(1):92-8. (IF:2.39)


 Published editorial comments

1. Ashfaq-Khan M, Schuppan Detlef. Subcellular localization of P21 protein in hyresponsive LPS-tolerant macrophages. Journal of Clinical Investigation 2016; E. Letter
2. Ashfaq-Khan M, Schuppan Detlef. Will Disabled Homology 2 (Dab2) Control Polarization of Tumour Associated Macrophages? Journal of Clinical Investigation 2016, E-Letter


Manuscripts submitted and in preparation

1. “Nutritional wheat amylase trypsin inhibitors promote murine obesity and non- alcoholic fatty liver disease”
2. Ashfaq-khan M, Aslam M, Qureshi MA, Weng SY, Kim YO, Pickert GA, Schattenberg JM, Schuppan D, (submitted)
3. “Combined treatment with Rapamycin and Zoledronic Acid strongly inhibits growth of murine hepatocellular carcinoma via activation of the immune microenvironment”
4.  Innate Lymphoid Cells Type 1 and 2 are Expanded in Early Stages of Hepatocellular Carcinoma in A Novel Murine Model Close to Human Hepatocarcinogenesis”
5. Ablation of Interleukin-4 Receptor alpha in macrophages ameliorated steatohepatitis and fibrosis in murine model of non-alcoholic steatohepatitis (NASH)
6. Wheat amylase trypsin inhibitors accelerate liver fibrosis in primary biliary fibrosis murine model

Recently published abstracts

1. Ashfaq-Khan M, Aslam M, Qureshi MA, Senkowski M, Weng SY, Schuppan, D. Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity April 2018, Journal of Hepatology.
2. Ashfaq-Khan M, Aslam M, Senkowski M, Weng SY, Schuppan D. Ablation of Interleukin-4 Receptor alpha in macrophages ameliorated steatohepatitis and fibrosis in murine model of non-alcoholic steatohepatitis (NASH). April 2018, Journal of Hepatology.
3. Aslam M, Ashfaq-Khan M, Qureshi MA, Senkowski M, Weng SY, Schuppan D. Zoledronic Acid suppresses tumour associated macrophages andmyeloid derived suppressor cells in murine HCC. April 2018, Journal of Hepatology
4. Aslam M, Ashfaq-Khan M, Qureshi MA, Senkowski M, Weng SY, Schuppan D. Rapamycin and Zoledronic acid exert a potent antifibrotic effect in murine biliary fibrosis, April 2018, Journal of hepatology
5. Aslam M, Pickert G, Ashfaq-Khan M, Schuppan, D.  Chemoprophylaxis of Azoxymethane/DSS-Induced Colonic Carcinogenesis in C57Bl/6 Mice using a Combination Therapy with Rapamycin and a Probiotic. May 2018, Gastroenterology
6. Pickert G, Rosigkeit S, Heck R, Ashfaq-Khan M, Schuppan D. Nutritional Wheat Alpha-Amylase/Trypsin Inhibitors Enhance Intestinal Inflammatory Monocytes and Aggravate Colonic Inflammation in DSS-Induced Colitis. May 2018, Gastroenterology
7. Heib V, Steinbach F, Rosigkeit S, Ashfaq-khan M, Schuppan D. Wheat Amylase/Trypsin Inhibitors Aggravate Oral Antigen Induced Food Allergy, May 2018, Gastroenterology.
8. Ashfaq-Khan M, Aslam, M. Qureshi MA, Weng SY, Schuppan, D. “Combined treatment with Rapamycin and Zoledronic Acid strongly inhibits growth of murine hepatocellular carcinoma via activation of the immune microenvironment”.  Hepatology, 2017; 66(1):4221A
9. Qureshi MA, Ashfaq-Khan M, Aslam, M. Hessel C, Senkowski1 M,  Gasteiger D, Schuppan  D. “Innate Lymphoid Cells Type 1 and 2 are Expanded in Early Stages of Hepatocellular Carcinoma in A Novel Murine Model Close to Human Hepatocarcinogenesis” Hepatology, 2017;66(1):412A
10. Aslam, M. Ashfaq-Khan, M, Qureshi MA, Kaps, L.  Weng SY, Senkowski M,  Nick M, Kim YO, Heck R, Surabattula R,  Schuppan D. “Zoledronic Acid suppresses tumour associated macrophages and myeloid derived suppressor cells boosting immune modulating therapies against murine HCC”. Hepatology, 2017; 66(1):421A
11. Aslam, M. Ashfaq-Khan, M, Qureshi MA, Kaps, L.  Weng SY, Senkowski M,  Nick M, Kim YO, Heck R, Surabattula R,  Schuppan D. “Rapamycin and zoledronic acid synergistically repolarize tumour associated macrophages towards anti-HCC responses” 2017, Journal of Hepatology
12. Aslam, M. Ashfaq-Khan M, Qureshi MA, Kaps L, Weng SY, Senkowski M,  Nick M, Kim YO, Heck R, Surabattula R,  Schuppan D. “Rapamycin and zoledronic acid synergistically repolarize tumour associated macrophages towards anti-HCC responses” 2017, Journal of Hepatology
13. Ashfaq-khan M, Misbah Aslam, Muhammad Asif Qureshi, Weng, Shih-Yen, Xiaoyu Wang, Zevallos, Victor, Kim, YO, Schuppan, Detlef. Nutritional Wheat Amylase Trypsin Inhibitors, Activators of Toll like receptor 4, exacerbate non-alcoholic steatohepatitis in High fat fed mice. November 2016. Journal of Hepatology